NCT04530682View on ClinicalTrials.gov

COVID-19 in Rheumatic Inflammatory Diseases Under Immuno-suppressive Drugs

CompletedOBSERVATIONAL
Enrollment

163

Participants

Timeline

Start Date

March 5, 2021

Primary Completion Date

June 23, 2022

Study Completion Date

February 15, 2024

Conditions
Chronic Inflammatory Rheumatism
Interventions
BIOLOGICAL

Biological samples

Serum and plasma samples. At baseline, 6, 12 and 24 months

Trial Locations (1)

34295

Centre hopsitalier universitaire de Montpellier, Montpellier

All Listed Sponsors
collaborator

French Society of Rheumatology

OTHER

lead

University Hospital, Montpellier

OTHER

NCT04530682 - COVID-19 in Rheumatic Inflammatory Diseases Under Immuno-suppressive Drugs | Biotech Hunter | Biotech Hunter